Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 581 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05901519RecruitingPhase 2
Prednisone to protect the liver during focused radiation for liver cancer
This trial tests whether prednisone (an anti-inflammatory steroid) can help protect the liver in people with hepatocellular carcinoma who are getting stereotactic body radiation therapy. It may reduce liver stress from radiation and help you tolerate treatment safely.
Ann Arbor, MichiganAges 18 years+ - NCT04365751Recruiting
Microwave ablation versus surgery for liver cancer
This trial compares two ways to treat hepatocellular carcinoma (a type of liver cancer): microwave ablation and laparoscopic hepatectomy (keyhole liver surgery). It may help find which option works better for tumor control and recovery in people with limited, non-spread cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04499833Recruiting
Test an AI score to guide liver transplant decisions
This study looks at a prediction tool that estimates outcomes for people with liver cancer and cirrhosis, to help decide whether a liver transplant is a good option. It may help doctors choose the right timing and patients who could benefit most from transplantation.
LisbonAges 18–70 - NCT05203120Recruiting
Proton beam radiation for liver cancer that can’t be removed
This study tests proton beam radiation for people with liver cancer that is still inside the liver but cannot be treated with surgery or a small-needle procedure. Proton beams aim to better target the tumor while reducing radiation to nearby organs.
Herlev, Capital RegionAges 18 years+ - NCT05926726Recruiting
GPC3-targeted CAR-T for advanced liver cancer
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
ShanghaiAges 18–75 - NCT05954897RecruitingPhase 2
Lenvatinib plus tislelizumab with HAIC for advanced liver cancer
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
Guangzhou, GuangdongAges 18 years+ - NCT05047510Recruiting
Fluorescent-guided surgery for liver cancer using GPC3 dye
This trial studies whether a special fluorescent dye that targets GPC3 can help surgeons find liver cancer more clearly during an operation. It may improve how accurately tumor tissue is identified while you have surgery for hepatocellular carcinoma.
Zhuhai, GuangdongAges 18–75 - NCT06044506RecruitingPhase 1
Natural killer cell therapy for liver cancer
This study tests an experimental therapy using your own natural killer cells to fight liver cancer. It may be an option if you have a specific stage of liver cancer and are generally in good health.
Jakarta Pusat, Jakarta Special Capital RegionAges 20–60 - NCT05444478Recruiting
Microwave ablation plus lenvatinib for recurrent liver cancer
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Changsha, HunanAges 18–75 - NCT07863258Recruiting
AI matchmaking for advanced liver cancer treatment
This study uses artificial intelligence to look at tumor samples and MRI scans from people with advanced liver cancer to help choose the best treatment. It aims to make treatment more personalized and effective.
AnderlechtAges 18 years+ - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+ - NCT05221398Recruiting
Immunotherapy after liver cancer surgery
This trial tests whether giving immunotherapy after surgery to remove liver cancer can help lower the risk of the cancer coming back. It may be an option for people who have certain risk factors for recurrence.
Nanning, GuangxiAges 18–75 - NCT06326502RecruitingPhase 1
A study of ETN101 for advanced liver cancer
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
SeoulAges 19–65 - NCT06241326Recruiting
Immunotherapy for liver cancer study
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
Nanjing, JiangsuAges 18 years+ - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT07848750Recruiting
Finger-press test for liver cancer detection
This study tests a new, non-invasive finger-press test that may help detect liver cancer (hepatocellular carcinoma). It compares results from people with liver cancer, people with benign liver disease, and healthy people to see if the test can tell them apart.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07840092Recruiting
Blood and tissue markers for liver cancer treatment response
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
TianjinAges 18 years+ - NCT07832006RecruitingPhase 2
Combination treatment for advanced liver cancer
This trial tests a combination treatment for advanced liver cancer that cannot be removed with surgery. It combines a procedure (irreversible electroporation) that uses electrical pulses to destroy cancer cells, with targeted therapy (lenvatinib) and immunotherapy (sintilimab) to help your immune system fight the cancer.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT07793695RecruitingPhase 2
Zinc plus immune therapy for advanced liver cancer
This study tests whether adding zinc supplements to standard targeted and immunotherapy improves outcomes for people with advanced liver cancer. Zinc may help the immune system work better against cancer cells.
Hefei, AnhuiAges 18–75 - NCT07795437Recruiting
New PET imaging tracer for liver cancer
This study tests a new imaging tracer to better see liver cancer on PET scans, which might help doctors find or monitor tumors more accurately.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06519578Recruiting
Liver Cancer Study: Comparing Two Chemotherapy Drugs via Artery Infusion
This study compares two chemotherapy drugs (raltitrexed and 5-fluorouracil) given directly into the liver's main artery to treat liver cancer. It aims to see which drug works better and is safer for people with hepatocellular carcinoma.
ShanghaiAges 18–75 - NCT07782632Recruiting
Imaging scans to predict immunotherapy response in liver cancer
This study looks at how doctors can use imaging scans to predict how well immunotherapy will work for people with liver cancer that cannot be removed by surgery. Participants must have already received immunotherapy and have had baseline scans.
Hefei, AnhuiAges 18–75 - NCT06581315Recruiting
Donafenib after surgery for high-risk liver cancer
This trial tests a drug called Donafenib (a targeted therapy) taken after surgery to see if it can prevent liver cancer from coming back in people at high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT06623474Recruiting
Fat markers in blood for liver cancer study
This study is for people having liver cancer surgery. It will look at certain fats in your blood to see if they can help doctors understand and track liver cancer better.
Guangzhou, GuangdongAges 18–80
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Hepatocellular Carcinoma trials by city
Studies with a site in or near these metro areas.
Hepatocellular Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 581 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.